Altay Therapeutics: The Biotech Targeting Transcription Pathways to Treat Chronic Liver Disease
The story of Altay Therapeutics, a Y Combinator-backed biotech pursuing small-molecule therapies that inhibit transcription factors to treat cirrhosis, NASH, and liver cancer — still in preclinical research and not yet approved by the FDA.
Think & Rich